Benefits

Neuralisse benefits, claim by claim

Last updated October 11, 2026Who wrote and checked this page

Neuralisse makes fewer claims than almost any product this desk has covered, and the ones printed on the bottle are drafted with real care. This page audits every one of them — the four on the label, the one that exists only in a marketing graphic, and the positioning line in the seller pack — against what is actually published about the six ingredients inside.

The label is careful and the artwork is not. Three of the four front-panel statements carry an asterisk leading to the FDA disclaimer, which the label prints in full. The bottle reads NERVE SUPPORT FORMULA. The Inside Neuralisse marketing graphic renders the same bottle as a NEUROPATHY SUPPORT FORMULA, and neuropathy is a named medical condition. Exactly one of the six claims has federal support: magnesium’s role in nerve impulse conduction, documented by the NIH Office of Dietary Supplements — and documented as a statement about deficiency.

Claims on the label: 4
Asterisked: 3 of 4
FDA disclaimer: Printed in full
Disease word on the bottle: None
Disease word in the artwork: Neuropathy
Claims with a federal file: 1 of 6
What that file describes: Deficiency
Ingredients with no file: 2 of 6

Every claim, transcribed

Six claims were supplied with this product. Four are printed on the bottle, one appears only in a marketing graphic, and one is the seller pack describing its own positioning. Nothing below is paraphrased.

Every claim supplied with Neuralisse, and where each one appears.
Claim	Where it appears
Nerve Support Formula	Printed on the label, front panel
Nerve Health*	Printed on the label, front panel icon
Comfort Support*	Printed on the label, front panel icon
Nutritional Support	Printed on the label, front panel icon
Neuropathy Support Formula	Marketing graphic only — not on the label
Nerve-comfort positioning by name. Not a drug.	Seller pack, in its own words

Read that list as a list and the first thing to notice is how short it is. There is no promise of relief, no timescale, no before-and-after, no percentage of users, no named outcome at all. Most sales packs in this category arrive with a paragraph of outcome language. This one arrived with four label statements and a sentence saying the product is positioned by name and is not a drug.

The second thing to notice is the fifth row. It is the only claim in the set that is not on the product, and it is the only one that names a disease. Everything else on this page follows from the distance between row one and row five.

What the label gets right

This is the best-drafted claim set in the series, and the credit belongs on the page before the criticism does. Here is the front panel as printed.

The front panel of the Neuralisse bottle, transcribed from the artwork supplied.
Detail	What we were actually given
Line 1	Neuralisse
Line 2	NERVE SUPPORT FORMULA* — the asterisk is on the label
Line 3	DIETARY SUPPLEMENT
Line 4	30 CAPSULES
Line 5	ONCE DAILY
Icon 1	NERVE HEALTH* — asterisked
Icon 2	COMFORT SUPPORT* — asterisked
Icon 3	NUTRITIONAL SUPPORT — no asterisk, and none needed
What the asterisks lead to	These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
A named disease anywhere on the bottle	None. The word neuropathy does not appear on the label artwork supplied.

Three asterisked structure/function statements and the disclaimer printed in full is exactly the shape the FDA’s own guidance describes. NERVE SUPPORT FORMULA*, NERVE HEALTH* and COMFORT SUPPORT* each describe a role rather than a result, and each carries the mark that tells a reader where the qualification is. The fourth icon, Nutritional Support, carries no asterisk and does not need one, because it asserts nothing about a body part at all.

That disclaimer is not decoration. It is the sentence the whole category turns on, and this label prints it rather than burying it:

“These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.”
Printed on the Neuralisse label

Several products in this series print a disclaimer that has been shortened, paraphrased, or set so small on the artwork that it cannot be read at the resolution supplied. This one prints both sentences in full. It is a small thing and it is also the difference between a label that has been drafted and a label that has been decorated.

Neuralisse — 30 capsules, one a day80 mg of magnesium at 19% of the Daily Value, inside a 575 mg blend of six. Guarantee as printed at checkout. No price is published anywhere but the checkout.

Order now See the three packs

The word the artwork adds

The Inside Neuralisse graphic supplied with this product renders the bottle twice, and both renderings read NEUROPATHY SUPPORT FORMULA. The bottle itself reads NERVE SUPPORT FORMULA. One word differs, and it is the word that moves the sentence across a line the FDA draws explicitly.

“Structure/function claims may describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the human body … the disclaimer must state that the product is not intended to “diagnose, treat, cure or prevent any disease,” because only a drug can legally make such a claim.”
U.S. Food and Drug Administration — Structure/Function Claims

Read the last clause of that quotation slowly, because it is the whole point: “only a drug can legally make such a claim”. Neuropathy is not a sensation or a body part. It is a named medical condition with causes that are diagnosed and, in many cases, treated. Nerve support describes a role. Neuropathy support names the thing being supported in disease terms.

This desk is not alleging that anyone intended to make a drug claim. Artwork gets drafted by different hands from labels, and a word swapped for a more searchable synonym is one of the commonest ways this happens. The point stands regardless of intent: the bottle a buyer receives is more careful than the picture that sold it to them, and when the two disagree the bottle is the product.

The asymmetry worth carrying away

The label earns marks here and the artwork gives them back. On the claim-accuracy line of this site’s own scoring the product takes 2 out of 5, and the note attached to that score says so in as many words: the label is careful, the graphic then renders the same bottle as a neuropathy support formula, and the one undoes the other. Finding 2 sets it out in full.

How a claim is checked here

The same seven steps are run on every product this desk covers. They are published so that a reader can disagree with the conclusion by pointing at the step rather than at the verdict.

01Read the claim off the bottle, not off the advertThe label is the product. Marketing artwork is a document about the product, and the two do not always say the same thing. On this product they differ by one word, and that word is the most consequential thing on this page.
02Decide which kind of claim it isA structure/function claim describes a role in the normal working of the body and must carry a disclaimer. A disease claim says a product treats a named condition, and the FDA is explicit that only a drug may make one. The asterisk on a label is the signal that the drafter knew which of the two they were writing.
03Find the asterisk, then find what it leads toThree of the four statements on the front panel carry one, and the disclaimer they lead to is printed in full on the artwork supplied. That is correct practice and it is recorded here as a credit rather than passed over.
04Ask which ingredient the claim has to rest onA claim about nerves has to be carried by something in the capsule. Six ingredients are named. The question is which of the six the claim depends on, because that is the one whose file has to be read.
05Ask what that ingredient weighsThis is where most of this label resolves. One printed figure — 80 mg of elemental magnesium — fixes the first ingredient at about 567.5 mg of a 575 mg blend, leaving roughly 7.5 mg for the other five together. Every figure after the first is a ceiling, not an amount.
06Take the ingredient to the two bodies this desk readsNCCIH and the NIH Office of Dietary Supplements. If a fact sheet exists it is quoted. If none exists, nothing is published here in either direction, and no journal is substituted for a federal file. Four of these six ingredients have a file; two return nothing.
07Read the file for what it actually describesThis is the step that decides the whole page. The magnesium file is real, it is federal, and it is about deficiency. A sentence describing what happens when a person does not have enough of a nutrient is not a sentence about what happens when a person who has enough takes more of it.

Six of the seven steps are mechanical. The seventh is where the work is, and it is where most pages about nerve supplements stop reading one sentence too early.

The audit, claim by claim

Each of the six claims put through the method above. The fourth column is the weight of whatever the claim has to rest on, and every figure in it after the magnesium row is a ceiling, not an amount.

Six claims, the ingredient each depends on, and what is published about it.
Claim	Names an outcome?	What it rests on	Weight	Federal file?
Nerve Support Formula	No — a role, not a result	Magnesium, the only nerve-relevant ingredient with a file	80 mg elemental, printed	Yes — NIH ODS
Nerve Health*	No	Magnesium	80 mg elemental, printed	Yes — NIH ODS
Comfort Support*	No — and comfort is not defined anywhere	Unstated. Nothing on the label says which ingredient carries it	—	Not applicable — no ingredient is named
Nutritional Support	No	The 80 mg magnesium declaration	19% of the Daily Value, correctly stated	Yes — NIH ODS
Neuropathy Support Formula	Yes — it names a disease	Nothing. No ingredient on this label has a published file about neuropathy	—	No
Nerve-comfort positioning by name. Not a drug.	No	The seller pack describing itself	—	Not applicable — it is a statement about the claim, not a claim

Four of the six rows resolve to the same place: the magnesium declaration. That is not a weakness in the audit, it is the shape of the product. A capsule whose blend is 98.7% one magnesium chelate is, functionally, a magnesium capsule with five other names printed on it, and any claim it makes has to be carried by the magnesium or by nothing.

The third row is the one with no answer at all. Comfort Support is asterisked, so it has been drafted as a structure/function claim, and nothing published says which of the six ingredients is supposed to deliver it. That is permitted and it is also unfalsifiable, which is why it appears in this table with a dash rather than a verdict.

The one claim with a federal file

This is the strongest ingredient-level support any product in this series has had for its own positioning, and it deserves to be quoted rather than summarised. The following is from the NIH Office of Dietary Supplements fact sheet on magnesium, copied exactly:

“Magnesium … helps move calcium and potassium ions across cell membranes, a process that is important to nerve impulse conduction, muscle contraction, and normal heart rhythm … As magnesium deficiency worsens, numbness, tingling, muscle contractions and cramps, seizures … can occur.”
NIH Office of Dietary Supplements — Magnesium: Fact Sheet for Health Professionals — nerve function

Everything in that quotation is true of this product’s principal ingredient. Magnesium is declared on the panel at 80 mg of the element. The label prints 19% of the Daily Value beside it, and that arithmetic is correct: ODS gives the Daily Value as 420 mg, and 80 divided by 420 is 19.05%. A correct percentage is a small thing to get right and most labels in this series do not.

80 mg against the two figures ODS publishesThe printed magnesium figure set beside the Daily Value and the upper limit.

One capsule80 mg

The Daily Value, NIH ODS420 mg

Upper limit for supplemental magnesium350 mg

10 mg100 mg1 g

The magnesium figure against the two numbers the NIH Office of Dietary Supplements publishes: a Daily Value of 420 mg, and a Tolerable Upper Intake Level of 350 mg for magnesium taken as a supplement. At 80 mg a capsule this product is at about 23% of that upper limit, which is a point in its favour.

So the magnesium row is complete in a way nothing else on this label is: the ingredient is named, the amount is printed, the percentage checks out, the form is specified, and a federal fact sheet describes a role for it in the exact system the product is sold for. Four products out of four in this series have claimed something about a body system. This is the first time the claim has landed on an ingredient with a file that mentions that system at all.

Deficiency is not relief

Here is where this page has to be precise, because the sentence above is the one most easily quoted out of shape. Read what the ODS file actually says, and then read what it does not say.

What the magnesium fact sheet establishes, and what it does not.
The ODS file says	Which means	It does not say
Magnesium helps move calcium and potassium ions across cell membranes	A described physiological role in nerve impulse conduction	That adding magnesium improves conduction in someone whose magnesium is adequate
As magnesium deficiency worsens, numbness, tingling, muscle contractions and cramps, seizures can occur	Those symptoms are among the consequences of a shortfall	That those symptoms, in any given person, are caused by a shortfall
The Daily Value is 420 mg for adults and children aged four and over	80 mg is 19% of a day’s reference intake, as the label states	That 19% of a Daily Value corrects a deficiency, or that a deficiency is present
The upper limit for supplemental magnesium is 350 mg for adults	80 mg is about 23% of that limit, which is a point in the product’s favour	Anything about effect. An upper limit is a safety figure, not a dose

The distinction this whole page turns on

A statement that a nutrient shortfall can cause numbness and tingling is not a statement that a nutrient supplement relieves numbness and tingling. The first is about correcting a deficit; the second is about treating a symptom. Nothing published by either body this desk reads makes the second statement about magnesium, and this site will not make it on their behalf. If you have numbness or tingling that a clinician has not explained, that is a reason to see one, because the causes are many and some of them need treating.

This matters commercially as well as medically. A buyer who is magnesium-deficient and a buyer who is not are buying two different things from the same bottle, and nothing on the label, in the artwork or in the seller pack distinguishes between them. The only way to know which buyer you are is a conversation with a clinician, and that is the one step no supplement page can do for anybody.

What the other five can carry

If the magnesium row is the product’s best case, the remaining five ingredients are the reason this page does not stop there. They are named prominently, two of them better than any label in this series manages, and they share about 7.5 mg between them.

01Start with the one printed figureThe panel declares 80 mg of magnesium above the blend and says it comes from the magnesium glycinate from proprietary blend. That is an amount of the element, not of the compound.
02Check that the label’s own percentage agreesThe panel prints 19% of the Daily Value beside it. The NIH Office of Dietary Supplements gives the Daily Value for magnesium as 420 mg, and 80 ÷ 420 = 19.05%. The label’s arithmetic is correct, which confirms the 80 mg is elemental magnesium.
03Work out what the compound weighsMagnesium bisglycinate is Mg(C₂H₄NO₂)₂. Its molar mass is 172.42 g/mol, of which magnesium accounts for 24.305. The chelate is therefore 14.1% magnesium by weight.
04Divide80 ÷ 0.141 = 567.5 mg of magnesium glycinate. That is the weight of the first ingredient in the blend, and it is not a ceiling — it is forced by a printed figure.
05SubtractThe blend is 575 mg. 575 − 567.5 = 7.5 mg for alpha lipoic acid, butcher’s broom, L-carnitine, turmeric and coenzyme Q10 together. The first ingredient is 98.7% of the blend.
06Apply the descending-order rule to what is leftThe FDA requires blend ingredients “in descending order of predominance by weight”, so inside that 7.5 mg remainder item n cannot exceed 7.5 ÷ n: at most 7.5, 3.7, 2.5, 1.9 and 1.5 mg. Every one of those is a ceiling, not an amount.

575 mg, resolvedOne printed figure, and what it forces on the rest of the blend.

Magnesium glycinateabout 567.5 mg

Everything else, togetherabout 7.5 mg

Alpha lipoic acidat most 7.5 mg

Butcher's broomat most 3.7 mg

L-carnitineat most 2.5 mg

Turmeric extractat most 1.9 mg

Coenzyme Q10at most 1.5 mg

1 mg10 mg100 mg1 g

The first bar is the one ingredient whose weight is fixed by a printed figure. The second is everything else in the blend added together. The five below it are the ceilings the descending-order rule puts on each one inside that remainder. A ceiling is a ceiling, not an amount.

One of the five has a published study range to be set against, and the comparison is the starkest this desk has published. The NIH Office of Dietary Supplements records L-carnitine trials at “0.25 to 4 g/day”, which is 250 to 4,000 mg. The ceiling here is about 2.5 mg — a ceiling, not an amount — which is between one hundred and one thousand six hundred times smaller than that range.

2.5 mg against the published trial rangeThe one ingredient here with a published dose range, set against it.

L-carnitine on this labelat most 2.5 mg

Lowest dose in the trials NIH ODS records250 mg

Highest dose in those trials4,000 mg

1 mg10 mg100 mg1 g10 g

The one ingredient on this label with a published study range, set against that range. NIH ODS records L-carnitine trials at “0.25 to 4 g/day”. The ceiling here is about 2.5 mg: between one hundred and one thousand six hundred times smaller. ODS also records that healthy adults do not need supplemental carnitine.

The same fact sheet adds that “healthy children and adults do not need to consume carnitine from food or supplements”, because the body makes enough. Turmeric, fifth in the blend at a ceiling of about 1.9 mg — again a ceiling, not an amount — is the best-named ingredient on the label and NCCIH is blunt about the evidence: “We don’t know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes.” Coenzyme Q10 is sixth at a ceiling of about 1.5 mg, and NCCIH records no finding for it on nerve symptoms at all.

Alpha lipoic acid and butcher’s broom return nothing at NCCIH’s Herbs at a Glance index and nothing at the NIH Office of Dietary Supplements. No dose and no effect is published here for either, and no journal is substituted, because choosing which papers to quote is the exact step that turns an information page into a sales page. All six rows are set out in full on the ingredients page.

What this page can and cannot state

A benefits page is only honest if its limits are printed beside its contents. Here are both columns.

What this page can state

Every claim supplied with this product, word for word, and exactly where each one appears.
That the label itself stays inside structure/function language: nerve support formula, three asterisked front-panel statements, and the FDA disclaimer printed in full.
That the marketing graphic renders the same bottle with a disease word the bottle does not use.
That magnesium is declared at 80 mg, that the label’s own 19% of the Daily Value is arithmetically correct, and that the NIH Office of Dietary Supplements documents a role for magnesium in nerve impulse conduction.
That the ODS sentence describes deficiency, and says what can happen as deficiency worsens.
That 80 mg is about 23% of the 350 mg upper limit ODS sets for supplemental magnesium.
A ceiling for each of the other five ingredients, and the full working behind every one.
That two of the six ingredients have no fact sheet at either body this desk reads.

What this page cannot state

That this product relieves nerve symptoms. Nothing published says so, and the label does not claim it either.
That magnesium supplementation relieves numbness or tingling in someone who is not deficient. The ODS file does not say that, and this page will not stretch it until it does.
That the product does not work. No trial of it exists, and absence of a trial is not a result.
How much of any of the five ingredients after the magnesium chelate a capsule contains. Every one of those figures is a ceiling, not an amount.
Anything at all about alpha lipoic acid or butcher’s broom, which return nothing at NCCIH and nothing at the NIH Office of Dietary Supplements.
What the product costs, or what the guarantee entitles a buyer to. Neither is published in any document supplied.

The second column is not an accusation and it is not a verdict. It is a list of questions with answers that exist somewhere — in a Certificate of Analysis, in a batch record, on a checkout screen — and that were not supplied to this desk. How to ask the order desk for the first two is set out here.

The findings behind this page

Three of the fifteen numbered findings bear directly on the claims. They are printed here in full so the audit above can be read against them.

02The marketing bottle carries a disease word the real label does not.

The flat label artwork reads NERVE SUPPORT FORMULA. The Inside Neuralisse marketing graphic renders the same bottle as NEUROPATHY SUPPORT FORMULA, twice. Neuropathy is a named medical condition. The FDA’s own page on structure/function claims explains that the mandatory disclaimer exists because a product is not intended to “diagnose, treat, cure or prevent any disease”, since “only a drug can legally make such a claim”. The label stays on the right side of that line. The artwork used to sell it does not.

12Magnesium has a real nerve-function file, and it is about deficiency.

NIH ODS states that magnesium is “important to nerve impulse conduction, muscle contraction, and normal heart rhythm”, and that as deficiency worsens “numbness, tingling, muscle contractions and cramps, seizures” can occur. That is the strongest ingredient-level support any product in this series has had for its positioning. It is a statement about correcting a deficiency, not about relieving a symptom in someone who has enough.

13The upper limit for supplemental magnesium is 350 mg, and this is well under it.

NIH ODS sets the Tolerable Upper Intake Level for supplemental magnesium at 350 mg for adults, and records that high doses “often result in diarrhea”. At 80 mg a capsule this product is at about 23% of that limit, which is a point in its favour and is recorded as one.

All 15 findings, numbered

References

Five sources bear on this page: the FDA’s own page on structure/function claims, both magnesium fact sheets, the carnitine fact sheet behind the dose comparison, and NCCIH on turmeric.

U.S. Food and Drug Administration (2026). Structure/Function Claims.
NIH Office of Dietary Supplements (2026). Magnesium: Fact Sheet for Health Professionals.
NIH Office of Dietary Supplements (2026). Magnesium: Fact Sheet for Health Professionals — nerve function.
NIH Office of Dietary Supplements (2023). Carnitine: Fact Sheet for Health Professionals.
National Center for Complementary and Integrative Health (2025). Turmeric: Usefulness and Safety.

Read the blend row before you decide

Thirty capsules, one a day. The panel declares 80 mg of magnesium at 19% of the Daily Value, and a 575 mg blend of six ingredients. The magnesium declaration fixes the weight of the first ingredient at about 567.5 mg, which leaves roughly 7.5 mg for the other five together. No price appears anywhere but the checkout.

1 bottle30 capsules30 days 3 bottles90 capsules90 days 6 bottles180 capsules180 daysNamed top pack

Order Neuralisse now Compare the packs

Guarantee as printed at checkout
80 mg magnesium, 19% of the Daily Value
Returns to 4 Times Square, Floor 22, New York, NY 10036, USA

No price appears in any document supplied to this desk, as of October 11, 2026, so none is printed here. The checkout screen is the only place a price exists. Questions first? Every published contact route is here.

Keep reading

Every documented cautionSix rows, with the source for each and a plain note where there is none.The panel, and the workingHow one printed figure resolves a 575 mg blend to 98.7 per cent.Who this is and is not forThe label's own restrictions, and the question to ask first.

Authorship and review

Who wrote and checked this page

Written byThe Neuralisse Editorial DeskLabel analysis and fact-checking

Medically reviewed byDr. Mark Runkle, DPM, PodiatristA named clinician or dietitian, once one has read these pages.

RoleMedical reviewerChecks the label transcription, the arithmetic and every safety statement on this page.

Review dateOctober 12, 2026The date a named reviewer signed off this page.

Who reviews these pages?

What this page was checked against

The label artwork, read at 2× and transcribed character for character. Where the label and the marketing disagree, the label is printed.
The seller pack, quoted rather than paraphrased, and identified as marketing wherever it is used.
The published sources listed in the references on this page. Every one was opened and read; none is cited from memory.
The arithmetic, shown in full. Every per-ingredient figure other than the magnesium is a ceiling derived from one printed number, never a measured amount.
Nothing else. Any fact that was not supplied is recorded as not published rather than filled in.

Last updated October 11, 2026. A highlighted slot is a value no human has supplied yet. Who reviews these pages?